| Population 2015 |
143 million |
| |
| | | | | |
| Estimates of TB burden*, 2015 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
15 |
(15–16) |
11 |
(10–11) |
| Mortality (HIV+TB only) |
1.5 |
(<0.01–7.4) |
1 |
(0–5.2) |
| Incidence (includes HIV+TB) |
115 |
(98–132) |
80 |
(69–92) |
| Incidence (HIV+TB only) |
11 |
(9.3–13) |
7.9 |
(6.5–9.4) |
| Incidence (MDR/RR-TB)** |
60 |
(49–71) |
42 |
(34–49) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2015 |
| |
0-14 years |
> 14 years |
Total |
| Females |
4.6 |
(2.8–6.4) |
31 |
(19–44) |
36 |
(21–50) |
| Males |
4.4 |
(3–5.8) |
74 |
(58–90) |
79 |
(61–96) |
| Total |
9 |
(6.8–11) |
106 |
(96–115) |
115 |
(98–132) |
| |
| | | | | |
| TB case notifications, 2015 |
|
| Total cases notified |
130 904 |
| Total new and relapse |
99 590 |
| - % tested with rapid diagnostics at time of diagnosis |
|
| - % with known HIV status |
|
| - % pulmonary |
93% |
| - % bacteriologically confirmed among pulmonary |
49% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2015 |
87% (75–100) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 |
0.15 (0.11–0.19) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2015 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
6 407 |
|
| - on antiretroviral therapy |
|
|
| |
| | | | | |
| Drug-resistant TB care, 2015 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
42 000
(35 000–48 000) |
| Estimated % of TB cases with MDR/RR-TB |
22% (14–25) |
53% (40–59) |
|
| % notified tested for rifampicin resistance |
38% |
31% |
46 641 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
|
| Laboratory-confirmed cases |
MDR/RR-TB: 17 132, XDR-TB: |
| Patients started on treatment **** |
MDR/RR-TB: 26 756, XDR-TB: 1 205 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2014 |
69% |
77 136 |
| Previously treated cases, excluding relapse, registered in 2014 |
42% |
5 790 |
| HIV-positive TB cases, all types, registered in 2014 |
|
|
| MDR/RR-TB cases started on second-line treatment in 2013 |
48% |
18 213 |
| XDR-TB cases started on second-line treatment in 2013 |
26% |
1 965 |
| |
| | | | | |
| TB preventive treatment, 2015 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
|
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
|
| |
| | | | | |
| TB financing, 2016 |
|
| National TB budget (US$ millions) |
1 385 |
| Funding source: 100% domestic, 0% international, 0% unfunded |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed | | |
| | | | | |